Im­mat­ics scores $75M up­front in TCR deal with Cel­gene as in­ter­est in tech bur­geons

Months af­ter el­e­vat­ing its chief sci­en­tist, Harpreet Singh, to the post of CEO, pri­vate­ly-held im­muno-on­col­o­gy com­pa­ny Im­mat­ics has en­list­ed an­oth­er part­ner — Cel­gene — in a deal cap­i­tal­iz­ing on the in­dus­try ap­petite for TCR ther­a­pies and their po­ten­tial to tar­get sol­id tu­mors — a lim­i­ta­tion of ex­ist­ing cel­lu­lar ther­a­pies.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER